The final report on this randomized, double-blinded, vehicle-controlled study to evaluate the safety, tolerability and efficacy of topically applied WBI-1001 cream in subjects with atopic dermatitis is expected later summer 2008.
The company has also initiated plans for a Phase IIb clinical trial to further evaluate the properties of WBI-1001 as a topical cream application against atopic dermatitis.